Robust quantitation of residual host cell and plasmid DNA & oncogenic fragments in HEK-based viral vector manufacturing
Cell & Gene Therapy Insights 2022; 8(8), 1245;
DOI: 10.18609/cgti.2022.182
Published: 16 October 2022
FastFacts
Watch the video or read the poster to learn more about:
- Current regulatory guidance on residual DNA test requirements and how this relates to typical viral vector process
- Data on residual DNA and fragment sizing assays suitable for validation per industry expectations to support process development and lot-release QC
- Clearance data from a typical AAV downstream process
- Design concept and specification for a novel rapid method for quantitation of various E1A fragment sizes